PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 29384916
OWN - NLM
STAT- MEDLINE
DCOM- 20180209
LR  - 20180209
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 52
DP  - 2017 Dec
TI  - Tranexamic acid reduces blood loss in intertrochanteric fractures: A
      meta-analysis from randomized controlled trials.
PG  - e9396
LID - 10.1097/MD.0000000000009396 [doi]
AB  - BACKGROUND: This meta-analysis aims to assess the efficacy and safety of
      tranexamic acid for reducing blood loss and transfusion requirements in patients 
      with intertrochanteric fractures. METHODS: We conduct electronic searches of
      Medline (1966-2017.09), PubMed (1966-2017.09), Embase (1980-2017.09),
      ScienceDirect (1985-2017.09), and the Cochrane Library. Only randomized
      controlled trials (RCTs) are included. The quality assessments are performed
      according to the Cochrane systematic review method. Fixed/random-effect model is 
      used according to the heterogeneity tested by I statistic. Meta-analysis is
      performed using Stata 11.0 software. RESULTS: A total of 4 RCTs are retrieved
      involving 514 participants. The present meta-analysis indicated that there were
      significant differences between groups in terms of total blood loss (weighted
      mean differences = -131.49, 95% confidence interval (CI): -163.63 to -99.35, P = 
      .00), hemoglobin decline (weighted mean differences = -0.31, 95% CI, -0.44 to
      -0.19, P = .00), and transfusion rate (risk differences = -1.11, 95% CI, -0.19 to
      -0.04, P = .00). In addition, no increased risk of adverse effects was identified
      in both groups. CONCLUSION: Local administration of tranexamic acid is associated
      with a reduced total blood loss, postoperative hemoglobin decline, and
      transfusion requirements in patients with intertrochanteric fractures.
      High-quality RCTs are still required for further investigation.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Wang, Weidong
AU  - Wang W
AD  - Department of Joint and Limbs Surgery, The Affiliated Yangming Hospital of Ningbo
      University, Yuyao People's Hospital of Zhejiang Province, Yuyao, China.
FAU - Yu, Jincong
AU  - Yu J
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antifibrinolytic Agents)
RN  - 6T84R30KC1 (Tranexamic Acid)
SB  - AIM
SB  - IM
MH  - Antifibrinolytic Agents/*therapeutic use
MH  - Blood Loss, Surgical/*prevention & control
MH  - Fracture Fixation, Internal/*adverse effects
MH  - Hip Fractures/*surgery
MH  - Humans
MH  - Randomized Controlled Trials as Topic
MH  - Tranexamic Acid/*therapeutic use
EDAT- 2018/02/01 06:00
MHDA- 2018/02/10 06:00
CRDT- 2018/02/01 06:00
PHST- 2018/02/01 06:00 [entrez]
PHST- 2018/02/01 06:00 [pubmed]
PHST- 2018/02/10 06:00 [medline]
AID - 10.1097/MD.0000000000009396 [doi]
AID - 00005792-201712290-00024 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(52):e9396. doi: 10.1097/MD.0000000000009396.